Sevirumab

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameSevirumab
Drug Alias Namesevirumabum司韦单抗司韦卢单抗ProtovirSDZ-MSL-109 +[7] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionCytomegalovirus (CMV) envelope glycoprotein H inhibitors
TargetsCytomegalovirus (CMV) envelope glycoprotein H
Therapy Area/IndicationsCytomegalovirus InfectionsHIV InfectionsCytomegalovirus Retinitis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSandozJohns Hopkins Bloomberg School Of Public HealthNational Institute Of Allergy And Infectious Diseases (Niaid) +[4] 
Active IndicationsN/A
Inactive IndicationsCytomegalovirus InfectionsHIV InfectionsCytomegalovirus Retinitis

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG